Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets

Background: Inflammatory breast cancer (IBC) is a poorly characterized form of breast cancer. So far, the results of expression profiling in IBC are inconclusive due to various reasons including limited sample size. Here, we present the integration of three Affymetrix expression datasets collected through the World IBC Consortium allowing us to interrogate the molecular profile of IBC using the largest series of IBC samples ever reported. Experimental Design: Affymetrix profiles (HGU133-series) from 137 patients with IBC and 252 patients with non-IBC (nIBC) were analyzed using unsupervised and supervised techniques. Samples were classified according to the molecular subtypes using the PAM50-algorithm. Regression models were used to delineate IBC-specific and molecular subtype-independent changes in gene expression, pathway, and transcription factor activation. Results: Four robust IBC-sample clusters were identified, associated with the different molecular subtypes (P < 0.001), all of which were identified in IBC with a similar prevalence as in nIBC, except for the luminal A subtype (19% vs. 42%; P < 0.001) and the HER2-enriched subtype (22% vs. 9%; P < 0.001). Supervised analysis identified and validated an IBC-specific, molecular subtype-independent 79-gene signature, which held independent prognostic value in a series of 871 nIBCs. Functional analysis revealed attenuated TGF-β signaling in IBC. Conclusion: We show that IBC is transcriptionally heterogeneous and that all molecular subtypes described in nIBC are detectable in IBC, albeit with a different frequency. The molecular profile of IBC, bearing molecular traits of aggressive breast tumor biology, shows attenuation of TGF-β signaling, potentially explaining the metastatic potential of IBC tumor cells in an unexpected manner. Clin Cancer Res; 19(17); 4685–96. ©2013 AACR.

[1]  S. Merajver,et al.  International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Rosette Lidereau,et al.  Molecular Profiling of Inflammatory Breast Cancer , 2004, Clinical Cancer Research.

[3]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[4]  F. Bertucci,et al.  Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’ , 2004, The Journal of pathology.

[5]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Joel S. Parker,et al.  Adjustment of systematic microarray data biases , 2004, Bioinform..

[8]  E. van Marck,et al.  Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression , 2003, British Journal of Cancer.

[9]  E. Gehan,et al.  The properties of high-dimensional data spaces: implications for exploring gene and protein expression data , 2008, Nature Reviews Cancer.

[10]  Y. Qi,et al.  Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer , 2011, Breast Cancer Research and Treatment.

[11]  S. Rotenberg,et al.  PhosphoMARCKS drives motility of mouse melanoma cells. , 2010, Cellular signalling.

[12]  Luc Y. Dirix,et al.  Distinct Molecular Signature of Inflammatory Breast Cancer by cDNA Microarray Analysis , 2005, Breast Cancer Research and Treatment.

[13]  E. Berns,et al.  Microarray-Based Oncogenic Pathway Profiling in Advanced Serous Papillary Ovarian Carcinoma , 2011, PloS one.

[14]  John N Weinstein,et al.  A stromal gene signature associated with inflammatory breast cancer , 2008, International journal of cancer.

[15]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[16]  P. Vermeulen,et al.  Inflammatory breast cancer: current understanding , 2006, Current opinion in oncology.

[17]  S. Merajver,et al.  Persistent E-Cadherin Expression in Inflammatory Breast Cancer , 2001, Modern Pathology.

[18]  E. van Marck,et al.  Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis , 2007, British Journal of Cancer.

[19]  Patrick Pauwels,et al.  Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination , 2010, PloS one.

[20]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[21]  References , 1971 .

[22]  W. Grizzle,et al.  Dual effects of TGF-β on ERα-mediated estrogenic transcriptional activity in breast cancer , 2009, Molecular Cancer.

[23]  Erik Sahai,et al.  Localised and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility , 2009, Nature Cell Biology.

[24]  Jelle J. Goeman,et al.  A global test for groups of genes: testing association with a clinical outcome , 2004, Bioinform..

[25]  Lajos Pusztai,et al.  Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. , 2007, The Lancet. Oncology.

[26]  Daniel Birnbaum,et al.  High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes , 2011, PloS one.

[27]  E. van Marck,et al.  Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[29]  D. Newgreen,et al.  Defining the E-Cadherin Repressor Interactome in Epithelial-Mesenchymal Transition: The PMC42 Model as a Case Study , 2010, Cells Tissues Organs.

[30]  F. Bertucci,et al.  Gene expression profiling of inflammatory breast cancer , 2010, Cancer.

[31]  Karen Margolis,et al.  Disclosure of Potential Conflicts of Interest , 2014 .

[32]  Rosette Lidereau,et al.  BMC Cancer BioMed Central Research article NF-kappa B genes have a major role in Inflammatory Breast Cancer , 2008 .

[33]  F. Bertucci,et al.  Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy , 2004, Cancer Research.

[34]  P. Dam,et al.  Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling , 2006, Breast Cancer Research and Treatment.

[35]  I. Van der Auwera,et al.  Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype , 2010, British Journal of Cancer.

[36]  E. Sahai,et al.  Intravital imaging illuminates transforming growth factor beta signaling switches during metastasis. , 2010, Cancer research.

[37]  Michael L. Gatza,et al.  A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.

[38]  Josef Gotzmann,et al.  Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. , 2004, Mutation research.

[39]  Daniel Birnbaum,et al.  Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. , 2005, Cancer research.